Article
Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.
BMC cancer - 28 Dec 2013
Jager Nynke G L, Koornstra Rutger H T, Vincent Andrew D, van Schaik Ron H N, Huitema Alwin D R, Korse Tiny M, Schellens Jan H M, Linn Sabine C, Beijnen Jos H
Abstract excerpt
BACKGROUND: Tamoxifen has dramatically reduced the recurrence and mortality rate of estrogen receptor positive breast cancer. However, the efficacy of tamoxifen varies between individuals and 40% of patients will have a recurrence despite adjuvant tamoxifen treatment. Factors that predict tamoxifen efficacy would be helpful for optimizing treatment. Serum concentrations of the active metabolite, endoxifen, may be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.